Previous 10 | Next 10 |
Total 2Q 2023 product revenue of $46.7 million Auvelity ® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi ® 2Q 2023 net product revenue of $19.1 million Pro forma second quarter cash balanc...
2023-08-05 06:55:00 ET What's a great thing to do during the hot month of August? One option is to find somewhere cool. Another is to invest in stocks that could deliver their own kind of sizzle. We asked three Motley Fool contributors to identify some fantastic growth stocks to buy...
2023-08-04 13:15:47 ET Axsome Therapeutics ( NASDAQ: AXSM ) is scheduled to announce Q2 earnings results on Monday, August 7th, before market open. The consensus EPS Estimate is -$1.20 (-13.2% Y/Y) and the consensus Revenue Estimate is $40.95M (+364.8% Y/Y). Over the l...
2023-08-03 09:45:00 ET The stock market is roaring back in 2023 following a downturn. However, the year hasn't been kind to every company. For instance, drugmakers AbbVie (NYSE: ABBV) and Axsome Therapeutics (NASDAQ: AXSM) have seen their shares lag the market since January....
2023-07-23 06:09:31 ET Summary Axsome Therapeutics' novel treatments for central nervous system disorders gain traction, with promising revenues from drugs Auvelity and Sunosi. Despite the current lack of profitability, Axsome shows potential for significant growth, buoyed by publ...
2023-07-20 08:08:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate about value investing, you must understand tha...
NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarte...
2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it has dosed the first patient in the FOCUS Phase 3 trial ...
2023-07-05 17:32:16 ET Gainers: Cardlytics, Inc. ( NASDAQ: CDLX ) +9% . Autolus Therapeutics ( AUTL ) +5% . Omeros ( OMER ) +4% . Arrival ( ARVL ) +3% . Nkarta ( NKTX ) +3% . Losers: IDEAYA Biosciences ( IDYA ...
News, Short Squeeze, Breakout and More Instantly...
Axsome Therapeutics Inc. Company Name:
AXSM Stock Symbol:
NASDAQ Market:
Axsome Therapeutics Inc. Website:
PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this se...
2024-07-15 07:15:00 ET Any stock can have an impressive run, especially when broader equities are experiencing a bull market. Significantly fewer stocks can perform well through good and not-so-good times and deliver excellent returns over long periods. These are precisely the sort of corpo...
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of ...